Ireland· IE-PA-PA0822/095/002
Premarin 0.625 mg Prolonged-release tablets
A conjugated estrogens product containing conjugated estrogens, registered in Ireland by Pfizer Healthcare Ireland Unlimited Company. The same ATC class is registered in 3 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Conjugated estrogens is registered in 3 of 19 countries.
Countries holding a registration under ATC G03CA57 (conjugated estrogens), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Conjugated estrogens · ATC G03CA57
3 / 19 countries
- Canada
- Finlandprice
- Ireland
The record
At a glance
HPRA (Ireland)- Active substance
- Conjugated estrogens
- Manufacturer
- Pfizer Healthcare Ireland Unlimited Company
- Country
- Ireland (IE)
- ATC code
- G03CA57
- ATC class
- Conjugated estrogens
- Defined daily dose
- 0.625 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0822/095/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
146 interactions on record for conjugated estrogens.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Conjugated estrogens · interactions on record
146 records
- 7 severe
- 136 moderate
- 3 minor
Most severe, free to view
- Tranexamic acidB02AA02severe
- HeminB06AB01severe
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Conjugated estrogens in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaPREMARINPFIZER CANADA ULC
- United StatesConjugated EstrogensPrasco Laboratories
- United KingdomConjugated oestrogens 1.25mg tabletsPfizer Ltd
- SpainEQUIN 0,6 mg COMPRIMIDOSLaboratorio Aldo Union S.L.
- FinlandPremarinWyeth Medica Ireland
- BelgiumDuavive 0.45 mg - 20 mgPfizer Europe MA
- Japan結合型エストロゲンファイザー
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Spain · Equín
- United Kingdom (Northern Ireland) · Conjugated Oestrogens Pfizer, Premarin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3c31f0d5-47fe-49ed-84e9-52495e788815 GET /v1/drugs/3c31f0d5-47fe-49ed-84e9-52495e788815?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Prolonged-release tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"G03CA",
"G03CA57"
],
"strength": null,
"pa_number": "PA0822/095/002",
"substances": [
"Conjugated estrogens"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "25/07/1988",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about conjugated estrogens.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.